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Abstract
Airway remodelling describes the histopathological changes leading to fixed airway obstruction in patients with asthma and
includes extra-cellular matrix (ECM) deposition. Matrix metalloproteinase-1 (MMP-1) is present in remodelled airways but its
relationship with ECM proteins and the resulting functional consequences are unknown. We used airway smooth muscle
cells (ASM) and bronchial biopsies from control donors and patients with asthma to examine the regulation of MMP-1 by
ECM in ASM cells and the effect of MMP-1 on ASM contraction. Collagen-I and tenascin-C induced MMP-1 protein
expression, which for tenascin-C, was greater in asthma derived ASM cells. Tenascin-C induced MMP-1 expression was
dependent on ERK1/2, JNK and p38 MAPK activation and attenuated by function blocking antibodies against the b1 and b3
integrin subunits. Tenascin-C and MMP-1 were not expressed in normal airways but co-localised in the ASM bundles and
reticular basement membrane of patients with asthma. Further, ECM from asthma derived ASM cells stimulated MMP-1
expression to a greater degree than ECM from normal ASM. Bradykinin induced contraction of ASM cells seeded in 3D
collagen gels was reduced by the MMP inhibitor ilomastat and by siRNA knockdown of MMP-1. In summary, the induction of
MMP-1 in ASM cells by tenascin-C occurs in part via integrin mediated MAPK signalling. MMP-1 and tenascin-C are co-
localised in the smooth muscle bundles of patients with asthma where this interaction may contribute to enhanced airway
contraction. Our findings suggest that ECM changes in airway remodelling via MMP-1 could contribute to an environment
promoting greater airway narrowing in response to broncho-constrictor stimuli and worsening asthma symptoms.
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Introduction
Asthma is a lung disease characterised by airway inflammation,
bronchial hyperresponsiveness and variable airway obstruction.
Chronic inflammation leads to a series of structural airway
changes collectively termed airway remodelling, which lead to
enhanced airway contraction and eventually fixed airflow
obstruction. Changes observed in airway remodelling include
epithelial desquamation, goblet cell hyperplasia, increased airway
smooth muscle (ASM) mass, thickening of the reticular basement
membrane and abnormal extracellular matrix (ECM) deposition.
The ECM is abnormal in terms of composition and quantity, with
increased expression of collagens, biglycan, elastin, fibronectin,
hyaluronan, laminin-b2, lumican, tenascin-C and versican when
compared with normal airways [1–5].
Matrix metalloproteinase-1 (MMP-1) is a collagenase, which is
minimally expressed in normal lung tissue [6–9]. However, in
patients with asthma, MMP-1 protein is present in the small
airways and lung parenchyma. In BAL fluid, MMP-1 mRNA is
directly correlated with airway obstruction. These observations
suggest that collagenase expression is associated with airway
narrowing and asthma symptoms although the mechanisms for
this are unclear [7,10,11]. We and others have previously
implicated ECM proteins as active mediators of airway remod-
elling with specific effects on airway epithelial integrity and repair,
ASM growth, differentiation, survival, synthetic function, migra-
tion and phenotype [12–17]. As MMPs are regulated by ECM
proteins in a number of systems, we hypothesised that the altered
ECM in asthma may increase the expression and activity of MMPs
and contribute to the asthma phenotype.
The relationship between ECM deposition, MMP-1 expression
and airway function is not understood, although interestingly,
collagenase treatment reduces passive tension and increases
muscle shortening in human bronchial smooth muscle strips
[18]. Collagenase treatment of ex vivo lung slices causes spontane-
ous airway narrowing [19] and inhalation of collagenase, increases
bronchial hyperresponsiveness in rodent models of asthma
[20,21]. In vitro models of airway contraction also show that
exogenous administration of MMP-1 can enhance airway
contraction and that the pro-contractile effects of the Th2
cytokines IL-4 and IL-13 are MMP-1 dependent [22,23].
Collectively these findings suggest that airway remodelling and
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ECM deposition could contribute to worsening airflow obstruction
and bronchial hyperresponsiveness by mediating the aberrant
expression of MMP-1 in the airways of patients.
Despite the potential importance of MMP-1 in asthma, few
studies have examined its regulation in ASM cells. ASM derived
MMP-1 mRNA and protein expression are upregulated by
collagen-I [17,22], platelet-derived growth factor [24], cyclic
strain [25], leukotriene D4 [26] and combined treatment with
TNF-a and IL-1b [27]. Understanding the roles of these asthma
relevant regulators upon bioactive proteins including MMP-1,
may provide novel therapeutic strategies to counter airway
remodelling. We therefore examined the regulation of MMP-1
by the ECM proteins which are differentially expressed in
remodelled airways and whether the resulting increase in MMP-
1 activity could functionally contribute to the asthma phenotype.
Materials and Methods
Endobronchial Biopsies and Culture of ASM Cells
Endobronchial biopsies were obtained from patients with
physician diagnosed asthma at British Thoracic Society stage II
or III, without history of an exacerbation or change in therapy for
at least 6 weeks [28]. Control endobronchial biopsy tissue was
obtained from patients undergoing bronchoscopy for other
reasons. Up to six endobronchial biopsies were taken from a first
or second order sub-carina by fibre-optic bronchoscopy according
to standard procedures. Biopsies were either formalin fixed and
embedded in paraffin for histological assessment or used for
culture of ASM cells as described previously [12]. ASM cells were
maintained at 37uC in a humidified incubator in 95% air/5%
CO2 and subcultured in DMEM (Sigma-Aldrich) supplemented
with 10% FCS, penicillin (50 U/ml) and streptomycin (50 mg/ml).
Cells were used between passage four and eight. A minimum of
three asthma donors and three control donors were used for all
experiments which were performed independently on at least three
occasions. The use of both ASM cells and biopsy tissue was
approved by the Nottingham Research Ethics Committee and
written, informed consent was obtained from all patients.
Coating Culture Plates with ECM Proteins
Tissue culture plates were incubated overnight with a 10 mg/ml
solution of collagen-I (Sigma-Aldrich, #C7774), collagen-IV
(Sigma-Aldrich, #C6746), fibronectin (Sigma-Aldrich, #F0895),
laminin (Sigma-Aldrich, #L6274) or tenascin-C (#CC065,
Millipore). Wells were washed with PBS, blocked with 1% BSA/
PBS and again washed with PBS as previously described [14]. For
cell derived ECM preparations, ASM cells from control and
asthma derived cells were cultured in 12-well culture plates for 14
days, media aspirated and cells removed using ammonium
hydroxide (50 mM) and Triton X-100 (0.05%). Following
incubation with DNase I (20 U/ml) plates were washed with
PBS and stored overnight (4uC). This preparation results in a cell
free bioactive ECM coating [29]. Plates were allowed to warm to
room temperature prior to seeding serum starved ASM cells, and
cell culture supernatants were harvested after 24 hours.
ECM Stimulation of ASM Cells
Experiments for determining MMP-1 secretion were initially
performed by seeding serum-starved ASM cells in serum-free
media onto tissue culture plates pre-coated with 10 mg/ml ECM
proteins as previously described [30] (Figure 1). MMP-1 expres-
sion induced by this method was not significantly different (n = 3,
p,0.05) from that induced by the addition of ECM to the culture
medium of cells adherent to tissue culture plastic and all
subsequent experiments were performed using soluble ECM
proteins. Unless otherwise stated, ASM cell culture supernatant
was harvested after 24 hours. An MTT assay was performed in
conjunction with each experiment according to a previously
described method [31] to ensure that ECM proteins did not affect
Figure 1. Induction of MMP-1 protein and activity by ECM
proteins. Serum starved ASM cells from three separate donors were
seeded on tissue culture plastic coated with ECM proteins (10 mg/ml)
for 24 hours. (a) ASM derived supernatants were assayed for total MMP-
1 expression by ELISA, (b) latent and active MMP-1 by western blotting
and (c) active and total MMP-1 expression using an MMP-1 specific
activity assay. Differences in MMP-1 protein expression were assessed
for statistical significance by 1-way ANOVA with post-hoc Dunnett’s
multiple comparison test (**P,0.01. ***P,0.001). Abbreviations: APMA,
4-aminophenylmercuric acetate; CI, collagen-I; CIV, collagen-IV; CT,
control; FN, fibronectin; LN, Laminin; TNC, tenascin-C.
doi:10.1371/journal.pone.0090565.g001
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cell number or have toxic effects. None of the ECM treatments
altered cell viability or increased cell number (data not shown).
MMP-1 Protein and Activity Determination
Total MMP-1 protein levels in cell culture supernatants, which
includes pro, active and inhibitor bound MMP-1, were quantified
by ELISA (Human Total MMP-1 DuoSet; DY901; R&D Systems)
and MMP activity using an MMP-1 specific activity assay (Human
Active MMP-1 Fluorokine E Kit; F1M00; R&D Systems)
according to manufacturer’s instructions. For specific activity
assay, samples were assayed with and without the addition of 4-
aminophenylmercuric acetate (APMA) which activates pro-MMPs
[32]. Total MMP-1 was inferred from the value for MMP-1
activity obtained after incubation of the samples with APMA. Pro-
and active MMP-1 species were differentiated by casein zymo-
graphy and immunoblotting in culture supernatants concentrated
ten-fold using Vivaspin 500 columns with recombinant human
pro-MMP-1 as a positive control.
For immunoblotting, equal quantities of supernatant were
diluted with 5x reducing gel loading buffer (1 M Tris, 0.1% SDS
(w/v), 0.08 DTT (w/v), 0.01% bromophenol (w/v) blue, 55%
glycerol (w/v)) heated to 95uC and spun at 13,000rpm for 3
minutes. Samples were resolved by electrophoresis on 10% SDS-
polyacrylamide gels and blotted onto a PVDF membrane.
Membranes were probed with a polyclonal anti-MMP-1 antibody
(Merck, #444209, 1/500) and a secondary HRP-conjugated
polyclonal goat anti-rabbit IgG antibody. Signals were visualized
using the ECL Western Blotting Detection Kit (Amersham
Biosciences). For casein zymography, supernatants were diluted
with an equal volume of 2x Novex sample buffer (Invitrogen) and
resolved by electrophoresis on 12% casein gels (Invitrogen) using
the Novex buffer system. Gels were incubated in Novex renaturing
buffer after electrophoresis followed by an overnight incubation in
Novex developing buffer at 37uC. Gels were incubated in colloidal
blue stain solution and destained overnight in water. Images were
acquired using SynGene GeneSnap v7.04 g attached to a
GeneGenius image acquisition system (Synoptics, Cambridge,
UK) [33].
Quantification of Gene Expression
RNA was extracted from ASM cells using an RNeasy Mini Kit
(Qiagen) and contaminating genomic DNA removed using DNAse
I (Qiagen). RNA was reverse-transcribed into cDNA using the
SuperScript II First-Strand Synthesis System for RT-PCR
(Invitrogen) with random hexamer primers according to manu-
facturer’s instructions. To determine the relative gene expression
levels of MMP-1, COL1A1 and TNC, cDNA was amplified by
quantitative real-time PCR using the Brilliant II SYBR Green
QPCR master mix (Agilent Technologies) with the primers listed
below. Reactions were performed in triplicate and the specificity of
the primers was confirmed for every PCR run by dissociation
curve analysis. Expression levels of target genes were determined
relative to a housekeeping gene GAPDH using the comparative
CT (22DDCT) method. The primers utilised are as follows:
COL1A1: F59-GAACGCGTGTCATCCCTTGT-39 R59-
GAACGAGGTAGTCTTTCAGCAACA-39 GAPDH: F59-
GGTCTCCTCTGACTTCAACA-39 R59-
AGCCAAATTCGTTGTCATAC-39 MMP1:F59-
GAGCAAACACACTGACCTACAGGA-39 R59-
TTGTCCCGATGATCTCCCCTGACA-39 TNC: F59-
CCACAATGGCAGATCCTTCT3-39 R59-
GTTAACGCCCTGACTGTGGT-39.
Immunodetection of Protein Phosphorylation
Protein phosphorylation was performed as previously described
[34]. ASM cells were lysed by 30 minute incubation in ice-cold
PhosphoSafe Extraction Reagent (Merck) containing a Complete
Protease Inhibitor Cocktail (Roche). Lysates were harvested and
insoluble cell debris was removed by centrifugation at 13,0006g
for 10 minutes at 4uC. Total cell lysate protein content from the
soluble fractions was quantified by the Bradford based Bio-Rad
protein assay kit to normalize protein content. Samples were
diluted in 5x reducing gel loading buffer (1 M Tris, 0.1% SDS (w/
v), 0.08 DTT (w/v), 0.01% bromophenol blue (w/v), 55% glycerol
(w/v)), heated to 95uC and spun at 13,000rpm for three minutes.
Samples were resolved by electrophoresis on 10% SDS-polyacryl-
amide gels and blotted onto a PVDF membrane. Membranes were
initially probed for: phospho-Akt (Ser473) (#4060, 1/1000),
phospho-Erk1/2 (Thr202/Tyr204) (#9106, 1/1000), phospho-
p38 MAPK (Thr180/Tyr182) and Phospho-SAPK/JNK
(Thr183/Tyr185) (#9251, 1/200). Following incubation with
primary antibodies, blots were incubated with a secondary HRP-
conjugated polyclonal antibody. Signals were visualized using the
ECL Western Blotting Detection Kit (Amersham Biosciences).
Subsequently membranes were stripped using Restore Western
Blot Stripping Buffer (Pierce) and reprobed for total expression of:
Akt (#2920, 1/1000); p44/42 MAPK (Erk1/2) (#9102, 1/1000);
p38 MAPK (#9212, 1/500); phospho-p38 MAPK (Thr180/
Tyr182) (#4511, 1/500) and SAPK/JNK (#9258, 1/200) which
were used for normalization. All antibodies were purchased from
cell signaling technologies. Alternatively, after 20 min of stimula-
tion with soluble tenascin-C (10 mg) ASM cell lysates (200 mg)
were analyzed by immunoblot for a panel of multiple phosphor-
ylated proteins (Human Phospho-MAPK Array Kit, #ARY002B,
R&D), according to the manufacturer’s instructions.
Inhibition of Protein Phosphorylation
ASM cells were treated with phosphorylation inhibitors
(SP600125, 10 mmol; U0126, 10 mmol; NS23766, 100 mmol;
SB208350, 10 mmol; rapamycin 10 nmol; wortmanin 100 nmol;
SB216763 10 mmol) for 30 minutes prior to stimulation with
tenascin-C (10 mg/ml). Cell culture supernatant was collected after
24 hours and assayed by ELISA for total MMP-1 concentration.
All inhibitors were purchased from Merck, apart from SB216763,
which was sourced from Sigma.
Receptor Expression and Inhibition
Cell surface expression of receptors was determined by flow
cytometry using methods previously described [35]. Briefly, ASM
cells were cultured in T75 cm2 tissue culture flasks, detached with
AccutaseH Cell Dissociation Reagent (Sigma), pelleted and re-
suspended in ice cold 2% BSA/PBS. Cells were incubated on ice
for 45 minutes with antibodies against integrin subunits b1 (R&D,
MAB17781) and b3 (Millipore, MAB2023Z), the avb5 integrin
(VWR, AB24694) and toll like receptor 4 (TLR4) (R&D, AF1478).
Polyclonal goat IgG (AB108C, R&D) was used as an isotype
control for TLR4 experiments and a monoclonal mouse IgG1
(MABC002, Millipore) as isotype control for integrin experiments.
All antibodies were used at 10 mg/ml. Cells were washed twice in
ice-cold 2% BSA/PBS solutions and incubated with the appro-
priate Alexa-Fluor 488 conjugated secondary antibody (Invitro-
gen). Cells were washed again, and fixed in a 1% formaldehyde/
PBS solution, which was removed prior to analysis. Flow
cytometry was performed using a Coulter FC 500 Flow Cytometer
(Beckman Coulter) and data analysed using flow cytometry data
analysis software (Weasel, The Walter and Eliza Hall Institute of
Medical Research). Integrin antibodies were also used for receptor
Regulation of MMP-1 by ECM in Asthma
PLOS ONE | www.plosone.org 3 February 2014 | Volume 9 | Issue 2 | e90565
blocking experiments. Experiments were performed on serum-
starved ASM cells seeded on uncoated tissue culture plastic. ASM
cells were treated with antibodies against the b1, b3 and the avb5
integrin (5, 10 or 20 mg/ml) or monoclonal mouse IgG1 isotype
control for 1 hour prior to stimulation with tenascin-C (10 mg/ml).
Cell culture supernatant was collected after 24 hours and assayed
by ELISA for total MMP-1 concentration. For each concentration
of each antibody type, MMP-1 concentration is expressed as a
percentage of that elicited by cells stimulated with the isotype
control at the corresponding concentration. Expression levels were
normalised to isotype control (at equivalent concentration,
stimulated with tenascin-C (10 mg/ml)).
Localisation of MMP-1 and Tenascin-C in Endobronchial
Biopsies
Immunohistochemistry was performed on sections cut from
formalin-fixed tissue embedded in paraffin blocks. Slides were
dewaxed in Histoclear (Fisher-Scientific) and rehydrated in a series
of graded alcohols. Slides were washed in water and PBS and
immersed in a 3% hydrogen peroxide solution for 10 minutes. To
block nonspecific binding sites, slides were incubated in horse
serum (2.5%) for 30 minutes. Sections were treated with anti-
MMP-1 (Merck, #444209, 1:200), anti-tenascin-C (Biohit,
#610003, 1:200) or isotype control antibodies overnight at 4uC
in an airtight humidified chamber. After washes with water and
PBS, primary antibodies were detected with ImmPRESS Univer-
sal Antibody (anti-mouse Ig/anti-rabbit Ig, peroxidase; Vector
Laboratories, #MP-7500) and visualized using the Vector VIP
Figure 2. Induction of MMP-1 protein and activity by tenascin-C is concentration dependent and transcriptionally mediated. ASM
cells from three different donors were stimulated with various concentrations of soluble tenascin-C for 24 hours. (a) ASM cell supernatant was assayed
for total MMP-1 expression by ELISA; (b) latent and active MMP-1 by western blotting (top panel) and casein zymography (lower panel, the latter
image is inverted to aid visualisation). Differences in MMP-1 protein expression were assessed for statistical significance by 1-way ANOVA with post-
hoc Dunnett’s multiple comparison test (**P,0.01. ***P,0.001). (c) MMP-1 mRNA from three donors stimulated with various concentrations of
soluble tenascin-C levels are expressed as fold change in cycle threshold number relative to untreated cells (normalised to GAPDH) and compared by
1-way ANOVA with post-hoc Dunnett’s Multiple comparison test. (d) ASM cells treated with 20 mg/ml tenascin-C or vehicle were cultured with and
without cycloheximide and MMP-1 mRNA analysed by paired one-tailed t-test (*P,0.05. ***P,0.001). Abbreviations: CHX, cycloheximide; ct, cycle
threshold.
doi:10.1371/journal.pone.0090565.g002
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substrate kit (Vector Laboratories, #SK-4600) and counterstained
with haematoxylin [35].
In vitro Contraction Assays
Serum starved ASM cells were suspended in a neutralized
solution of bovine collagen-I (Sigma-Aldrich; C4243) and 10x
DMEM (Sigma-Aldrich) and cast in 24-well tissue culture plates to
create 7 mm-thick three dimensional (3D) collagen gels. Gels were
allowed to set for 24 hours before being overlaid with DMEM.
After 16 hours, gels released from wells and transferred to 6-well
plates containing DMEM/F12 (Sigma-Aldrich) [36]. Contraction
was stimulated with bradykinin (Sigma-Aldrich). Gel contraction
was quantitated over 60 minutes using Genesnap camera
(Genetools, Syngene, and Cambridgeshire, UK) with the reduc-
tion in initial gel area quantitated using Image J (http://rsb.info.
nih.gov/ij). In experiments involving MMP inhibition, gels were
treated with 10 mM ilomastat (Sigma-Aldrich) 1 hour prior to
bradykinin stimulation.
siRNA Inhibition of MMP-1
siRNA was used as described with the following modifications
[12]. ASM cells were transfected with Lipofectamine 2000
(Invitrogen), Opti-MEM and 20 nM of siRNA (Selleck Chemicals)
according to manufactures instructions. Two separate MMP-1
specific siRNA sequences were used, both of which caused a
similar reduction in MMP-1 protein assessed by ELISA. An
unrelated control siRNA sequence transfected using the same
protocol had no effect on MMP-1 expression. For all siRNA
experiments, MMP-1 specific sequences were compared with the
control siRNA. Knockdown of MMP-1 expression was confirmed
at 24 hours and at the end of contraction experiments by MMP-1
ELISA.
Figure 3. Induction of MMP-1 protein by tenascin-C is ERK1/2, JNK and p38 dependent. (a) ASM cells were stimulated with soluble
tenascin-C (10 mg/ml). Lysates were harvested at 20 minutes and assayed by immunoblot for a panel of phosphorylated signalling proteins using
proteome profiler. (b) ASM cells from three normal donors were stimulated with soluble tenascin-C (10 mg/ml). Lysates were harvested at 20 minutes
and 24 hours, with levels of total and phosphorylated signalling proteins assayed by Western Blotting. (c) ASM cells from three normal donors were
incubated for 30 minutes with inhibitors of JNK (SP600125, 10 mmol), MEK1/2 (U0126, 10 mmol), Rac1 (NS23766, 100 mmol), p38 (SB208350, 10 mmol),
mammalian target of rapamycin complex 1 (rapamycin 10 nmol), PI3K (wortmanin 100 nmol) or glycogen synthase kinase ab (GSK3ab, SB216763
10 mmol) prior to stimulation with tenascin-C (10 mg/ml). Supernatant was harvested after 24 hours and assayed for MMP-1 protein. Expression levels
were normalised to vehicle control (0.02% DMSO, tenascin-C (10 mg/ml)) and analysed using a 1-way ANOVA with post-hoc Dunnett’s multiple
comparison test (*P#0.05. ***P,0.001).
doi:10.1371/journal.pone.0090565.g003
Regulation of MMP-1 by ECM in Asthma
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Statistical Analysis
Statistical analysis was performed using the Prism 5 for windows
(version 5.02, 1992-2009 GraphPad Software, Inc. US). Data are
presented as mean 6 SEM. A p-value ,0.05 was considered to be
significant.
Results
MMP-1 is Induced by Extracellular Matrix Proteins
To determine if MMP-1 could be regulated by ECM proteins of
relevance to airway remodelling: ASM cells were cultured on
collagen-I, collagen-IV, fibronectin, laminin and tenascin-C.
Although all matrix substrates enhanced total MMP-1 protein in
culture supernatants, there were robust and significant rises in
MMP-1 in ASM grown upon collagen-I and tenascin-C (figure 1a).
This finding was supported by western blot analysis of culture
supernatants showing increased expression of the 54 kDa pro-form
of MMP-1 particularly in collagen-I and tenascin-C treated cells.
In tenascin-C treated cells the two active species of MMP-1 were
also detected (figure 1b). We then used a specific MMP-1 activity
assay which showed increased active and total MMP-1 in a similar
pattern to the ELISA, particularly in tenascin-C treated cells
(figure 1c). Comparable trends were observed for all donors
studied.
Tenascin-C dose Dependently Enhances MMP-1
Expression and Activity
As tenascin-C strongly induced MMP-1 expression and activity
and is expressed in the airways of patients with asthma, tenascin-C
was studied in detail. There was a concentration dependent
increase in MMP-1 protein in supernatants of ASM cells cultured
with tenascin-C as determined both by ELISA and western
blotting (figure 2a, b). Active 45 kDa MMP-1 became detectable
using western blotting when cells were exposed to concentrations
of tenascin-C of 10 mg/ml or greater (figure 2b). Casein
zymography, a substrate based assay, was used to further
investigate these findings, caseinolytic activity was observed
Figure 4. Selective inhibitors of Rac1, JNK, ERK1/2 and p38 dose dependently block the induction of MMP-1 by tenascin-C. ASM cells
from three normal donors were incubated with (a) U0126; (b) SB203580; (c) NSC23766; (d) SP200125 at indicated concentrations, prior to stimulation
with soluble tenascin-C (10 mg/ml). Supernatant was harvested after 24 hours and assayed for MMP-1 protein. The white bar represents the vehicle
control (0.02% DMSO) and the black bar represents the stimulated vehicle control (0.02% DMSO and tenascin-C (10 mg/ml)).
doi:10.1371/journal.pone.0090565.g004
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corresponding to the molecular mass of pro and active MMP-1 in
supernatants from tenascin-C stimulated cells (figure 2b). We next
used real time PCR to determine if tenascin-C also elicited a
change in levels of MMP-1 mRNA. Tenascin-C dose dependently
increased the expression of MMP1 mRNA at 6 hours (figure 2c).
Addition of cycloheximide to ASM cultures had no effect on
mRNA induction by tenascin-C suggesting this was a direct effect
on the MMP1 promoter which did not involve synthesis of other
proteins (figure 2d).
Tenascin-C Mediated Induction of MMP-1 is via JNK, p38
and ERK1/2 MAPKs
To determine the signalling pathways regulating tenascin-C
induced MMP-1 secretion, we took a dual approach examining
the effect of a range of signalling inhibitors on tenascin-C induced
MMP-1 protein expression and the intermediates phosphorylated
by tenascin-C after at 20 minutes and 24 hours. p38 MAPK was
phosphorylated after 20 minutes of tenascin-C exposure whereas
Akt, MEK 1/2 and JNK were phosphorylated after 24 hours of
tenascin-C exposure as shown by phosphoarray and western
blotting (figure 3a & b). Enhanced expression of MMP-1 was
blocked by inhibitors of JNK (SP600125, 10 mmol), MEK1/2
(U0126, 10 mmol), Rac1 (NS23766, 100 mmol) and p38
(SB208350, 10 mmol) (figure 3c). Inhibition of mammalian target
of rapamycin complex 1 (rapamycin 10 nmol), PI3K (wortmanin
100 nmol) and glycogen synthase kinase-3 ab (SB216763
10 mmol) did not attenuate tenascin-C induced MMP-1 expression
(figure 3c). We then went on to show that U0126, SB208350,
NS23766 and SP600125 had dose dependent effects of on the
inhibition of tenascin-C induced MMP-1 production (figure 4).
Tenascin-C Induces MMP-1 Expression via b1 and b3
Integrins
To determine which receptors were responsible for tenascin-C
stimulated MMP-1 expression we performed flow cytometry for
the candidate tenascin-C receptors expressed by ASM cells, TLR4
and b1, b3 and avb5 integrins. TLR4 was not expressed by
unstimulated ASM (data not shown) but b1, b3 and avb5 were
present on the majority of ASM cells (figure 5a). We next treated
ASM with blocking antibodies against these integrin subunits and
showed a dose dependent inhibition of tenascin-C stimulated
MMP-1 expression for b1 and b3 but not avb5 when compared
with an isotype control antibody (figure 5b).
Tenascin-C Stimulated MMP-1 Expression is Enhanced in
Asthma
To determine if tenascin-C regulates MMP-1 in disease, we
examined the expression of tenascin-C and MMP-1 in the airways
from five control donors and seven patients with asthma. Neither
tenascin-C nor MMP-1 protein was expressed in normal airways
from non-smokers. In patients with asthma there was strong
expression of both tenascin-C and MMP-1 in the sub-epithelial
Figure 5. Tenascin-C induced MMP-1 secretion is mediated by the b1 and b3 integrin subunits. (a) ASM cells processed for flow cytometry
were incubated with antibodies against the integrin subunits b1, b3 and the avb5 receptor prior to incubation with a fluorescently conjugated
secondary antibody. Histogram depicts fluorescence intensity detected by flow cytometry (one representative experiment of three shown) for
antigens (shaded) and their respective isotype control (broken line). (b) ASM cells were incubated with the same antibodies as listed above prior to
stimulation with tenascin-C (10 mg/ml). Supernatant was harvested after 24 hours and assayed for MMP-1 protein. Expression levels analysed using a
2-way ANOVA with post-hoc Dunnett’s Multiple comparison test (*P#0.05. ****P#0.0001). Graph depicts results normalised to the isotype control
(stimulated with tenascin-C (10 mg/ml)) at equivalent concentration, representative experiment of three separate donors is shown.
doi:10.1371/journal.pone.0090565.g005
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basement membrane and smooth muscle bundles (figure 6).
Isotype control antibodies for both MMP-1 and tenascin-C caused
no colour reaction (data not shown). We then compared MMP-1
expression in ASM cells obtained from six patients with asthma
and six controls. Asthma derived ASM had higher basal
expression of MMP-1 and higher tenascin-C stimulated MMP-1
levels than control ASM cells (figure 7a). Comparison of ASM cells
from three control and four asthma donors showed no significant
difference in expression of the b1, b3 and avb5 integrins. Further,
the use of integrin blocking antibodies showed that inhibition of
the b3 integrin subunit blocked MMP-1 production to the same
degree as control cells (figure 7b).
As increased ECM deposition is a feature of airway remodelling
in asthma, we hypothesised that asthma derived ASM may secrete
increased levels of ECM proteins resulting in enhanced MMP-1
production by an autocrine mechanism. We therefore compared
gene expression of tenascin-C and collagen-I in four asthma and
three control ASM cell cultures by real-time PCR. Compared with
control ASM, asthma derived cells had significantly increased
collagen-I but similar levels of tenascin-C gene expression
(figure 7c). To determine if this change in ECM expression by
asthma derived ASM could be responsible for the enhanced
MMP-1 secretion we generated ECM preparations from three
control and five asthma derived ASM cultures. Both ECM
preparations strongly induced MMP-1 expression in three
unstimulated control ASM cultures when compared to tissue
culture plastic. This induction was significantly greater on ECM
derived asthma cells when compared with control ASM (figure 7d).
MMP-1 Facilitates Airway Smooth Muscle Cell
Contraction in vitro
Having shown that ECM proteins can induce the expression of
MMP-1 by ASM, and that these proteins are co-localised in the
airways of patients with asthma, we examined whether MMP-1
had functional consequences for airway contraction. We used an
assay which examines contraction of ASM in 3D collagen gels. In
initial experiments 3D ASM gels contracted in response to the
ASM contractile agonists, serotonin, carbachol and bradykinin to
a mean (SD) value of 82.7% (1.4), 87.3% (0.8) and 48.4% (8.8) of
the original area after 60 minutes respectively (all p,0.005). There
was a robust dose dependent contraction in response to bradykinin
(figure 8a) which was used for further experiments. ASM cells
suspended in 3D collagen gels strongly expressed MMP-1. Pre-
treatment of gels with ilomastat (10 mmol) reduced bradykinin
induced contraction when compared with vehicle controls
(figure 8b). We then used siRNAs against MMP-1, which reduced
MMP-1 expression in gel supernatants by eight fold compared
with control siRNA (figure 8c). Transfection of ASM cells with this
siRNA resulted in a significant reduction in gel contraction
compared with control siRNA (figure 8d).
Figure 6. Expression of tenascin-C and MMP-1 in the airway. Endobronchial biopsies from seven patients with asthma and five controls
stained for MMP-1 and tenascin-C. Representative images of smooth muscle bundles and epithelium are shown with positive staining visible as violet
colouration. Original magnification6100.
doi:10.1371/journal.pone.0090565.g006
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Discussion
The data presented here demonstrate that the production and
activation of MMP-1 by ASM is regulated by ECM proteins
present in the airways of patients with asthma. Both collagen-I and
tenascin-C enhanced MMP-1 expression with tenascin-C also
inducing the active form of MMP-1. As the regulation of MMP-1
by collagens has been studied in detail previously [17,37,38] we
focused on the effects of tenascin-C, which we have shown
increased levels of latent and active MMP-1 protein via b3-
integrin mediated MAPK signalling. Asthma derived ASM in vitro
had higher basal expression levels of MMP-1 and upregulated
MMP-1 expression in response to tenascin-C via a b3-integrin
sensitive mechanism in common with normal cells. Asthma
derived ASM cells produced more collagen-I under basal
conditions than normal cells and ECM deposited by asthma
derived cells had a greater capacity to induce MMP-1 secretion
than control ECM. Of functional relevance to asthma, MMP-1,
collagen-I and tenascin-C are co-located in the airways of patients
with asthma and ASM derived MMP-1 facilitated the agonist
induced ASM contraction in vitro. Our findings would suggest that
increased MMP-1 in asthma biopsies and asthma ASM cells is the
result at least in part of abnormal deposition of ECM. Previous
work has suggested that pro-inflammatory cytokines including
IL1b and TNFa [39,40] and cyclic strain [25] also induce MMP-1
expression in ASM and are likely to be of relevance to asthma.
Figure 7. Asthma ASM cells secrete greater quantities of MMP-1 protein than control cells and control by ECM. (a) Six asthma derived
and six control ASM cultures were incubated for 24 hours with and without the addition of soluble tenascin-C (10 mg/ml). The supernatant was
harvested and levels of total MMP-1 assessed by ELISA. Expression levels were analysed using an unpaired one-tailed t-test (*P,0.05. **P,0.01). (b)
ASM cells from four asthma and three control donors were incubated with a b3 integrin subunit function blocking antibody prior to stimulation with
tenascin-C (10 mg/ml). Supernatant was harvested after 24 hours and assayed for MMP-1 expression. Expression levels for control and asthma ASM
were separately normalised to an equivalent concentration of an isotype control, stimulated with tenascin-C (10 mg/ml). (c) Three control ASM cell
cultures were seeded on ECM deposited by ASM cells from six asthma and six control donors. After 24 hours total MMP-1 was assessed by ELISA.
Expression was analysed using a 1 way ANOVA with post-hoc Dunnett’s Multiple comparison test (**P,0.01. ***P#0.001). (c) Serum starved ASM cells
from four asthma and three control donors were seeded onto tissue culture plastic for six hours and TNC or COL1A1 mRNA assessed by qRT-PCR.
Levels are expressed as mean fold change in cycle threshold number relative to GAPDH and compared by paired t-test (*P,0.05).
doi:10.1371/journal.pone.0090565.g007
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This is the first study to show tenascin-C can induce MMP-1
expression in primary human cells [41–43], and whilst avb3
integrin mediated MMP-1 induction has been documented
[44,45], our study demonstrates this response can also be initiated
by tenascin-C. This mechanism involved tenascin-C dependent
p38 phosphorylation; which had previously only been indirectly
inferred by inhibitor studies [46–48]. Tenascin-C contains
multiple cell interaction domains having differing effects in
differing cell types [49]. Integrins a2b1 and avb3 are involved
in many of these processes with the avb3 integrin interaction
mediated by the peptide sequence SRRGDMS in endothelial cells
implicating an RGD dependant mechanism [50]. In addition, the
avb3 specifically binds tenascin-C via its fibrinogen-like domain
[51].
Despite the presence of ECM proteins, particularly collagen-I
and laminin within the normal airway, MMP-1 expression is
minimal. In patients with both mild and fatal asthma there is both
an increase in constitutively expressed ECM proteins and re-
expression of proteins normally restricted to the developing lung
including tenascin-C and some laminin isoforms. In these patients,
we and others observed expression of MMP-1 within the ASM
bundles [7]. As MMP-1 expression by ASM is regulated by ECM
proteins in vitro, this indicates the complex ECM environment in
the asthmatic airway has the potential to alter MMP-1 expression
by the presence of tenascin-C and collagen-I. This is consistent
with our findings that asthma derived ASM cells produce more
MMP-1 and a functionally different ECM. Although we show that
unstimulated asthma derived cells have similar tenascin-C gene
Figure 8. MMP expression and activation enhances ASM contraction. (a) Bradykinin-stimulated contraction of 3D collagen gels containing
ASM cells is concentration dependent. (b) Ilomastat pretreatment (10 mmol) reduces bradykinin induced contraction when compared with vehicle
control. Changes are analysed using a two way Repeated-Measures ANOVA with post-hoc bonferroni multiple comparison (c) siRNA against MMP-1
reduces MMP-1 expression in 3D collagen gel supernatants and analysed using a one way ANOVA with post-hoc Dunnet’s multiple comparison test
(d) siRNA against MMP-1 reduces ASM contraction compared with transfection of a control siRNA and analysed by two way Repeated-Measures
ANOVA with post-hoc bonferroni multiple comparison test. Graphs represent mean +/2SE of four replicate gels from three donors repeated on three
occasions. (**P,0.01. ***P#0.001).
doi:10.1371/journal.pone.0090565.g008
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expression to normal ASM, the Th2 cytokine IL-13, can strongly
induce tenascin-C expression by ASM suggesting the asthma
phenotype may induce ASM to synthesise tenascin-C [52,53].
These observations suggest that in the remodelled airways of
patients with asthma, ECM proteins act together to induce MMP-
1 expression.
It is unknown whether MMP-1 expression confers pathogenic
or protective effects in airway remodelling. A simple interpretation
of its role is to function as a negative regulator of excessive ECM
deposition. However, previous studies demonstrate potentially
pro-remodelling roles for MMP-1, including promotion of ASM
proliferation [7,26]. Additionally, MMP processed collagen-I
generates b3-integrin ligands which can induce tenascin-C
expression in vascular smooth muscle [54], raising the possibility
that tenascin-C induced MMP-1 induction may be a self-
sustaining process. Ovalbumin challenge of sensitised tenascin-C
knockout mice results in lower levels of airway reactivity,
monocyte chemoattractant protein-1, IL-5, IL-13 and IgE in
bronchoalveolar lavage fluid [55]. As specific features of airway
remodelling have been associated with asthma severity [56], it
suggests elements of airway remodelling may sustain airway
inflammation and bronchial hyperresponsiveness. In our study
ASM were derived from patients with asthma using inhaled
corticosteroids. To our knowledge there are no data linking the use
of these drugs with MMP-1 expression in asthma: it will be
important to determine how corticosteroids affect MMP-1
expression both via direct effects and indirectly through the
modulation of inflammatory mediators.
We sought to investigate the contractile function of ASM
derived MMP-1. Contraction was assessed using a collagen gel
contraction assay, which involves suspending ASM cells within a
collagen-I matrix. We chose to use a ‘restrained’ matrix
contraction model, which involves a period of culture with the
gel attached to the culture surfaces, creating tension within the
matrix. When the gel is released, further contraction occurs as
mechanical stress dissipates [57]. Cells within the restrained 3D
matrix develop pseudopodia and integrin-dependent collagen
adhesions. Integrin engagement triggers structural and signalling
protein translocation to the cell membrane and focal adhesion
assembly. Gel contraction is dependent on actin polymerisation
and the resulting force transferred through focal adhesions to the
surrounding collagen [58]. Contraction occurs due to iterative
cycles of pseudopodia extension, focal adhesion development,
collagen adhesion, pseudopodia retraction and collagen release via
a mechanism dependent on the integrins, actin stress fibre
development and myosin II assembly [57,59].
Contraction in response to bradykinin was attenuated when
cells were treated with a broad spectrum MMP inhibitor and
siRNAs against MMP-1, suggesting MMP-1 contributes to
contraction in a non-redundant manner. MMP-1 localises to the
tips of pseudopodia and collagen proteolysis has been shown to
promote the formation of pseudopodia, collagen reorganisation
and focal adhesion destruction [60,61]. This suggests that MMP-1
promotes the dynamic behaviour required to elicit gel contraction.
Consistent with these findings, in vitro studies of ASM collagen gels
suggest that MMP-1 can alter the structure of collagen fibrils [17]
and that asthma derived ASM is more contractile in this system
[23,36]. Furthermore, acetylcholine induced airway contraction
and contraction velocity within murine lung slices was enhanced
by collagenase incubation [19], which was attributed to a decrease
in airway wall stiffness and collagen degradation. As in our study,
the effect of collagenase in intact airways had a finite but
physiologically relevant effect on contraction which suggests that
the effect is one of a number of factors contributing to airway
narrowing.
Taken together, these findings suggest that, the induction of
MMP-1 by abnormal ECM in the airways of patients with asthma
may result in reduced airway stiffness, enhanced airway narrowing
in response to bronchoconstrictor stimuli and worsening asthma
symptoms. The absence of tenascin-C in control tissue, deposition
in asthma and proximity to MMP-1 expression denote tenascin-C
as a potential, pathologically-relevant, regulator of MMP-1
expression in vivo and target for therapeutic intervention against
airway remodelling. Further studies in human asthma are required
to determine whether this mechanism contributes to bronchial
hyper-responsiveness and if so, how the expression and activation
of MMP-1 is driven by pro-inflammatory factors during exacer-
bations and the effect of asthma treatment, particularly cortico-
steroids.
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